Introduction
Lialda, a brand name for the drug mesalamine, is a crucial medication in the treatment of various inflammatory bowel diseases (IBD), including ulcerative colitis, Crohn's disease, proctitis, and others. Here, we delve into the market analysis and sales projections for Lialda, highlighting key drivers, market size, growth rate, and competitive landscape.
Market Size and Growth Rate
The global mesalamine (Lialda) market has been experiencing steady growth. As of 2022, the market size was valued at approximately $156.5 million[1].
- By 2032, the market is projected to reach $220.21 million, exhibiting a Compound Annual Growth Rate (CAGR) of 3.1% from 2022 to 2032[1].
- Another forecast suggests a CAGR of 3 to 5% from 2021 to 2031, indicating a consistent growth trajectory[3].
Driving Factors
Several factors are driving the growth of the mesalamine market:
- Increasing Incidence of IBD: The rising prevalence of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease is a significant driver. As more people are diagnosed, the demand for effective treatments like mesalamine increases[1][2][3].
- Improved Diagnostic Methods: Advances in diagnostic techniques have led to earlier and more accurate diagnoses, which in turn increase the demand for therapeutic options like Lialda[1].
- Patient Awareness: Greater awareness among patients regarding medical treatments for IBD has also contributed to the market growth[1].
Applications and Product Forms
Mesalamine is used in various forms and for multiple applications:
- Applications: The drug is used to treat conditions such as colitis, Crohn's disease, proctitis, diarrheal irritable bowel syndrome, diverticulitis, and other related disorders[2][3].
- Product Forms: Mesalamine is available in several formulations, including enemas, tablets, suppositories, and other forms, catering to different patient needs and preferences[3].
Geographical Segmentation
The mesalamine market is segmented geographically into:
- North America: A significant market due to high healthcare spending and advanced diagnostic capabilities.
- Europe: Another major market with a high incidence of IBD.
- Asia-Pacific: This region is expected to grow rapidly due to increasing healthcare infrastructure and awareness.
- South America and Middle East & Africa: These regions also contribute to the global market, though to a lesser extent[2][3].
Competitive Landscape
The mesalamine market is competitive, with several key players:
- Dr.Falk Pharma
- Ferring
- Ethypharm Pharmaceutical
- Shanghai Pharmaceutical
- Tillotts Pharma
- Holy Stone Healthcare
- Giuliani
- Zeria
- Lupin
- Heilongjiang Tianhong Pharmaceutical
- HENGCHENG PHARMACEUTICAL
- KWAI FA Pharmaceutical Group[1][2][3].
Impact of Generic Competition
The introduction of generic versions of Lialda has impacted the market. For instance, Zydus Cadila received FDA approval for a generic version of Lialda, which has six-month exclusivity. This development is expected to affect Shire's revenues, though the impact is projected to be minimal, with a 2% to 3% hit on revenues and 4% to 6% hit on earnings per share through fiscal 2020[5].
Market Research and Analysis
Market research reports on mesalamine (Lialda) are comprehensive, involving both qualitative and quantitative data:
- Research Methodology: Reports are prepared through primary and secondary research, including face-to-face interviews, surveys, and expert opinions[2].
- Segmentation: The market is segmented by application, product form, and geography to provide a detailed analysis[2][3].
Future Outlook
The future outlook for the mesalamine market is positive, driven by increasing demand and advancements in healthcare:
- Market Size Projections: By 2032, the market is expected to reach $220.21 million, indicating a steady growth trajectory[1].
- CAGR: The market is expected to grow at a CAGR of 3.1% to 5% over the forecast period, reflecting a stable and growing market[1][3].
Key Takeaways
- The global mesalamine (Lialda) market is expected to grow from $156.5 million in 2022 to $220.21 million by 2032.
- The market is driven by the increasing incidence of IBD, improved diagnostic methods, and patient awareness.
- The drug is available in various forms and is used to treat several IBD-related conditions.
- The market is geographically segmented, with North America and Europe being significant contributors.
- Key players include Dr.Falk Pharma, Ferring, Ethypharm Pharmaceutical, and others.
- Generic competition, though present, is not expected to significantly impact the market in the short term.
FAQs
What is the expected market size of the mesalamine (Lialda) market by 2032?
The global mesalamine (Lialda) market is expected to touch $220.21 million by 2032[1].
What is the CAGR of the mesalamine (Lialda) market from 2022 to 2032?
The mesalamine (Lialda) market is expected to exhibit a CAGR of 3.1% from 2022 to 2032[1].
What are the driving factors of the mesalamine (Lialda) market?
The driving factors include the increasing incidence of IBD, improved diagnostic methods, and increased patient awareness regarding medical treatments[1].
Which companies are the top players in the mesalamine (Lialda) market?
Top companies include Dr.Falk Pharma, Ferring, Ethypharm Pharmaceutical, Shanghai Pharmaceutical, Tillotts Pharma, and others[1][2][3].
How has the introduction of generic versions affected the market?
The introduction of generic versions, such as the one by Zydus Cadila, is expected to have a minimal impact on Shire's revenues, with a projected 2% to 3% hit on revenues and 4% to 6% hit on earnings per share through fiscal 2020[5].
What are the different forms in which mesalamine is available?
Mesalamine is available in various forms, including enemas, tablets, suppositories, and other forms[3].
Sources
- Business Research Insights: Mesalamine (Lialda) Market Size, Share | Global Report 2032.
- Verified Market Reports: Mesalamine (Lialda) Market Size, Share & Trends | Growth, 2030.
- Market Research Intellect: Global mesalamine lialda market size and forecast.
- Dataintelo: Mesalamine Lialda Market Research Report 2032.
- FiercePharma: Shire's $800M Lialda confronted by generic competition but Zydus copy will fly solo for now.
